MTOR and brain stem glioma: PDGFRA‐high OPC‐like cells are enriched in DMG, consistent with reports of frequent PDGFRA alterations (amplifications or mutations) in pediatric brainstem gliomas [53] Given PDGFRA's role in the PI3K/AKT/mTOR pathway, it represents a promising therapeutic target, particularly as several PDGFRA inhibitors which are already in clinical development.